{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:25:33Z","timestamp":1782714333482,"version":"3.54.5"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department of Education of the Basque Government"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Treatment of GCA still requires substantial exposure to glucocorticoids (GCs), which are associated with significant toxicity. This study compares the efficacy and safety of the GC-only standard of care (SOC) with a regimen combining intravenous methylprednisolone (IVMP) pulses, MTX and lower doses of prednisone, in newly diagnosed patients with GCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A usual clinical practice study was conducted in three Spanish academic hospitals. One hundred and fifty-one patients diagnosed with GCA were treated with SOC prednisone (40\u201360\u2009mg\/d) or with IVMP (125\u2013500\u2009mg\/d \u00d73) followed by lower-dose prednisone (\u226430\u2009mg\/d) and MTX (IVMP\/MTX), with a follow-up of 2\u2009years. A propensity score was used to adjust for baseline differences in the multivariate analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-nine (52.3%) patients received SOC prednisone and 72 (47.7%) IVMP\/MTX. The clinical characteristics at baseline were similar in both the groups. Hundred percent patients achieved remission after a median time of 4\u2009weeks, without differences between the groups. Relapse rates were also similar. Patients receiving IVMP\/MTX had significantly lower cumulative GC doses and reached prednisone \u22645\u2009mg\/d faster than SOC patients (mean 13.8 vs 56.5\u2009weeks; P\u2009&amp;lt;\u20090.001). Patients in the IVMP\/MTX group were less likely to suffer any GC-related adverse effect (adjusted OR 0.35, 95% CI 0.14\u20130.85; P\u2009=\u20090.021).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination IVMP\/MTX with lower-dose prednisone is as effective as the SOC in inducing remission and preventing relapses in GCA. The IVMP\/MTX scheme significantly reduces GC exposure and GC-associated adverse effects. IVMP\/MTX could be a potential GC-sparing strategy, especially in patients with GCA at higher risk of GC toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf499","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:08:55Z","timestamp":1757678935000},"source":"Crossref","is-referenced-by-count":2,"title":["Methylprednisolone plus MTX-based regime vs prednisone-based standard of care for GCA: a propensity score study"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8959-8683","authenticated-orcid":false,"given":"Adriana","family":"Soto-Peleteiro","sequence":"first","affiliation":[{"name":"Biobizkaia Health Research Institute, Autoimmune Diseases Research Unit, Hospital Universitario Cruces , Bizkaia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-2015","authenticated-orcid":false,"given":"Jos\u00e9","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7923-5422","authenticated-orcid":false,"given":"F\u00e1tima","family":"Raad","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7105-9470","authenticated-orcid":false,"given":"Borja","family":"de Miguel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Acha","sequence":"additional","affiliation":[{"name":"Biobizkaia Health Research Institute, Autoimmune Diseases Research Unit, Hospital Universitario Cruces , Bizkaia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Torio","sequence":"additional","affiliation":[{"name":"Biobizkaia Health Research Institute, Autoimmune Diseases Research Unit, Hospital Universitario Cruces , Bizkaia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9992-9148","authenticated-orcid":false,"given":"Halbert","family":"Hernandez-Negrin","sequence":"additional","affiliation":[{"name":"Biobizkaia Health Research Institute, Autoimmune Diseases Research Unit, Hospital Universitario Cruces , Bizkaia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-6925","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"G\u00f3mez-Caverzaschi","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9628-4022","authenticated-orcid":false,"given":"Ioana","family":"Ruiz-Arruza","sequence":"additional","affiliation":[{"name":"Biobizkaia Health Research Institute, Autoimmune Diseases Research Unit, Hospital Universitario Cruces , Bizkaia,","place":["Spain"]},{"name":"Department of Medicine, University of the Basque Country, UPV\/EHU , Bizkaia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-1880","authenticated-orcid":false,"given":"Olga","family":"Araujo","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-597X","authenticated-orcid":false,"given":"Sergio","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8299-0209","authenticated-orcid":false,"given":"Georgina","family":"Esp\u00edgol-Frigol\u00e9","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C","family":"Cid","sequence":"additional","affiliation":[{"name":"Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1043","authenticated-orcid":false,"given":"Guillermo","family":"Ruiz-Irastorza","sequence":"additional","affiliation":[{"name":"Biobizkaia Health Research Institute, Autoimmune Diseases Research Unit, Hospital Universitario Cruces , Bizkaia,","place":["Spain"]},{"name":"Department of Medicine, University of the Basque Country, UPV\/EHU , Bizkaia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2026020205381062100_keaf499-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026020205381062100_keaf499-B2","first-page":"S8","article-title":"Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies","volume":"33","author":"Romero-G\u00f3mez","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2026020205381062100_keaf499-B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/md.0b013e31803d1764","article-title":"Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study","volume":"86","author":"Gonz\u00e1lez-Gay","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"2026020205381062100_keaf499-B4","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205381062100_keaf499-B5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","article-title":"Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis","volume":"41","author":"Cid","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2026020205381062100_keaf499-B6","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","article-title":"Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism","volume":"107","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2003","journal-title":"Circulation"},{"key":"2026020205381062100_keaf499-B7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art1.10161","article-title":"A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis","volume":"47","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2026020205381062100_keaf499-B8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","article-title":"Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis","volume":"43","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205381062100_keaf499-B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026020205381062100_keaf499-B10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026020205381062100_keaf499-B11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0025-7125(05)70511-3","article-title":"Giant cell arteritis and polymyalgia rheumatica","volume":"81","author":"Hunder","year":"1997","journal-title":"Med Clin North Am"},{"key":"2026020205381062100_keaf499-B12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med"},{"key":"2026020205381062100_keaf499-B13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"2026020205381062100_keaf499-B14","doi-asserted-by":"publisher","first-page":"120638","DOI":"10.1155\/2013\/120638","article-title":"Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series","volume":"2013","author":"Diamantopoulos","year":"2013","journal-title":"Biomed Res Int"},{"key":"2026020205381062100_keaf499-B15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2026020205381062100_keaf499-B16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"2026020205381062100_keaf499-B17","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2026020205381062100_keaf499-B18","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026020205381062100_keaf499-B19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026020205381062100_keaf499-B20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2026020205381062100_keaf499-B21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020205381062100_keaf499-B22","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S2665-(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026020205381062100_keaf499-B23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med"},{"key":"2026020205381062100_keaf499-B24","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026020205381062100_keaf499-B25","first-page":"1484","article-title":"A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients","volume":"27","author":"Chevalet","year":"2000","journal-title":"J Rheumatol"},{"key":"2026020205381062100_keaf499-B26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026020205381062100_keaf499-B27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026020205381062100_keaf499-B28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrm1009","article-title":"Nongenomic actions of steroid hormones","volume":"4","author":"Losel","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026020205381062100_keaf499-B29","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/rheumatology\/keae459","article-title":"The use of intravenous methylprednisolone in giant cell arteritis: a population-based study","volume":"64","author":"Henningson","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205381062100_keaf499-B30","first-page":"S-90-7","article-title":"Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients","volume":"33","author":"Les","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2026020205381062100_keaf499-B31","doi-asserted-by":"publisher","first-page":"e001355","DOI":"10.1136\/rmdopen-2020-001355","article-title":"Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses","volume":"6","author":"Fl\u00f3rez","year":"2020","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf499\/64285070\/keaf499.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf499\/64285070\/keaf499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf499\/64285070\/keaf499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:38:24Z","timestamp":1770028704000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf499\/8255771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf499","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,16]]},"article-number":"keaf499"}}